Search the Newsreel

ICL Group (NYSE:ICL) Upgraded by Wall Street Zen to "Buy" Rating

Wall Street Zen has upgraded ICL Group (NYSE:ICL) from a "hold" to a "buy" rating, despite a broader analyst consensus remaining "Hold" with an average price target of $6.00. This upgrade follows ICL Group's recent quarterly results, which surpassed expectations with an EPS of …

LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded LB Pharmaceuticals (NASDAQ:LBRX) from "hold" to "sell" despite a broader analyst consensus of "Moderate Buy" with an average price target of $47.75. The company recently reported a quarterly loss of $1.71 per share, missing consensus estimates, and analysts anticipate a …

NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded NRx Pharmaceuticals (NASDAQ:NRXP) from a "hold" to a "sell" rating, despite other analysts maintaining a "Moderate Buy" consensus with an average price target of $34.50. The company's stock opened at $3.27, reflecting a 2.1% drop, and recently reported a …

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Verrica Pharmaceuticals (NASDAQ:VRCA) from a "sell" to a "strong sell" rating. Despite this, the stock has a consensus "Hold" rating and an average target price of $14.50 from other analysts. The company recently reported a quarterly loss of $0.41 per …

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

BioCryst Pharmaceuticals reported a significant profit swing in Q2 2026, with revenue of US$218.25 million and net income of US$78.4 million, prompting a raised full-year revenue outlook to US$690 million–US$715 million. Despite this strong quarter, the company still faces a substantial year-to-date net loss …

Kothari Petrochemicals standalone net profit declines 3.19% in the June 2026 quarter

Vishnu Chemicals hosts virtual analyst meet on Aug 19, 2026

Aarey Drugs & Pharmaceuticals standalone net profit declines 25.55% in the June 2026 quarter

(RIGL) Price Dynamics and Execution-Aware Positioning

This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) focusing on its price dynamics and execution-aware positioning based on AI models. It identifies strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels above the current price, and outlines specific …

Marine Electricals (India) consolidated net profit rises 48.75% in the June 2026 quarter

Primo Chemicals consolidated net profit rises 14.71% in the June 2026 quarter

Bhilwara Technical Textiles consolidated profit up in Q1FY27; standalone down

ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside

The average 12-month price target for ACADIA Pharmaceuticals Inc. (ACAD) stock has been lowered from $33.65 to $33.05 by 19 analysts, with a range of $17 to $41 per share. This new target suggests a potential 17% upside based on the August 14 closing …

Hansoh Pharmaceutical Group Stock Sheds 1.7% in Hong Kong

California Water Service director Krummel sells $186,350 in shares

Thomas M. Krummel, a director at California Water Service Group (NYSE:CWT), sold 3,700 shares of the company's common stock for $186,350 on August 13, 2026. This transaction follows stronger-than-expected Q2 2026 results for the utility provider, which reported increased earnings per share and revenue. …

Kiniksa Pharmaceuticals International, plc Class A Revenue Breakdown – BIVA:KNSA/N

Kiniksa Pharmaceuticals International, plc (BIVA:KNSA/N) generated 12.21 billion MXN in revenue last year, primarily from its Therapeutic Medicines segment. The United States was the largest contributor to this revenue, accounting for 12.20 billion MXN. This represents an increase from the previous year's segment revenue …

Quoin Pharmaceuticals | 10-Q: Quarterly report

This document is a quarterly report (10-Q) filed by Quoin Pharmaceuticals. It contains financial statements and other important disclosures required by the Securities and Exchange Commission for the reporting period.

Alpha Metallurgical Resources (AMR) Reports Weaker Quarterly Results, Does It Look Fairly Valued?

Nicola Greenway (TAK) plans sale of 12,980 Takeda ADSs after RSU vesting

Nicola Greenway has filed a notice to sell 12,980 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited, derived from vested Restricted Stock Unit Awards. The planned sale is scheduled for August 14, 2026, through Interactive Brokers LLC. This follows previous sales on August …

Syndax Pharmaceuticals (SNDX) Moved, What Is Behind The Fresh Attention?

Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals

Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals, Inc., had 2,500 Performance Share Units (PSUs) vest on August 12, 2026. Following the vesting, 1,158 shares were withheld by the company at $46.57 per share to cover tax …

California Water Service Group Director Thomas M. Krummel Sells 3,700 Shares at $50.37 Each

California Water Service Group Director Thomas M. Krummel sold 3,700 shares of the company's common stock at $50.365 per share on August 13, 2026. This transaction was reported in a Form 4 filed with the SEC, reducing Krummel's direct ownership to 20,103.922 shares. The …

InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares

Ikarian Capital, LLC and Neil Shahrestani have jointly reported a 4.2% beneficial ownership stake in InMed Pharmaceuticals Inc. (INM), totaling 137,634 common shares. This ownership, held through Ikarian Healthcare Master Fund, L.P. and separately managed accounts, is based on 3,314,063 common shares outstanding as …

Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary

Processa Pharmaceuticals (PCSA) reported a net loss of $(3.27M) and diluted EPS of $(1.19) for the third quarter of 2026, showing an improvement from the previous year, with no product revenue. The company recently acquired Vidya, securing $200M in funding to advance new clinical …

Universal Technical Institute (UTI) Q1 2024 Earnings Report - Results, Call & Slides

Vivani Medical (NASDAQ: VANI) Completes Full Enrollment In Semaglutide Implant Trial, Strikes Novo Nordisk Deal

Vivani Medical (NASDAQ: VANI) announced full enrollment in its SLIM-1 Phase 1 trial for NPM-139, a semaglutide implant, with top-line data expected in November 2026. The company also signed a non-exclusive agreement with Novo Nordisk for evaluating NPM-139 and its NanoPortal technology. Additionally, Vivani …

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’

Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock

Universal Technical Institute director DeVincenzi buys $25,945 in shares

Robert Thomas DeVincenzi, a director at Universal Technical Institute Inc. (NASDAQ:UTI), purchased 1,000 shares of the company's common stock for $25,945. This transaction increased his direct holdings to 149,330 shares. The purchase occurred as the stock trades near $25.20, down 13% over the past …

NRx Pharmaceuticals (NASDAQ:NRXP) Issues Earnings Results, Misses Estimates By $0.35 EPS

Staar Surgical Co (STAA) Shares Surge 3.4% -- What GF Score of 80 Tells Investors

Staar Surgical Co (STAA) shares surged 3.4% to $26.19, with a GF Score of 80/100, indicating strong overall performance. The stock is considered "Modestly Undervalued" by GuruFocus, with a potential upside of 21.8% from its current price, although its high P/E ratio and lack …

PMV Pharmaceuticals (NASDAQ:PMVP) Posts Earnings Results, Beats Expectations By $0.05 EPS

PMV Pharmaceuticals (NASDAQ:PMVP) reported a quarterly loss of $0.34 per share, beating analyst expectations by $0.05. Following the announcement, the stock rose 3.7% to $1.26. Analysts maintain a "Moderate Buy" rating with a $4.00 consensus price target, despite Oppenheimer lowering its target to $5.00.

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.98 per share a year ago. These figures are adjusted for non-recurring items. This …

Discipline and Rules-Based Execution in BCRX Response

This article provides an AI-driven analysis for Biocryst Pharmaceuticals Inc. (BCRX), highlighting strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 15.0% gain. It details three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for …

(AUPH) Risk Channels and Responsive Allocation

The article analyzes Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), highlighting a weak near-term sentiment despite potential long-term strength. It details an exceptional 43.3:1 risk-reward setup targeting an 11.7% gain versus 0.3% risk, and provides AI-generated institutional trading strategies for various risk profiles. The analysis includes …